Bioasis Technologies (BIOAF) 1.0700 $BIOAF
biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC
Marketwired - Thu Apr 21, 5:28PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company"
announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC ("Astellas" . The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the internalization and assessment of the biOasis Transcend technology.
BTI.VN: 1.390 (unch)
biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain
Marketwired - Thu Mar 17, 10:37PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company" on Saturday, March 19, 2016 at 11:45am, will present the data from the biOasis sponsored Brains for Brain ("B4B" lysosomal storage disease ("LSD" knockout mouse study performed by Dr. Maurizio Scarpa and Dr. Rosella Tomanin at Dr. Scarpa's laboratories in Padova, Italy. Dr. Scarpa is a world leading clinical expert in lysosomal storage diseases.
BTI.VN: 1.390 (unch)
biOasis Technologies Inc. - Product Pipeline Review Market Size, Share & Forecast to 2015: Radiant Insights, Inc
M2 - Fri Jan 22, 3:06AM CST
Summary
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 36.67 (-0.18), SPPI: 6.82 (-0.02), BMY: 74.66 (-1.81), STML: 7.45 (-0.06), ONTY: 1.21 (+0.02), NKTR: 16.10 (+0.93), MEIP: 1.36 (-0.02), ATNM: 1.75 (+0.05), ABBV: 64.72 (-0.18), EXEL: 8.95 (+0.19), NVS: 82.08 (-0.81)
Kalytera Therapeutics elects Ronald P. Erickson to board
M2 - Fri Dec 04, 6:05AM CST
Pharmaceutical company Kalytera Therapeutics revealed on Thursday the addition of Ronald P. Erickson to its board of directors.
Kalytera Therapeutics Appoints Ronald P. Erickson to Board of Directors
Marketwired - Thu Dec 03, 6:08PM CST
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid ("CBD" and synthetic CBD medicines intended to address the unmet needs of large patient populations, today announced it has appointed Ronald P. Erickson to its Board of Directors.
biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
Marketwired - Sun Nov 29, 2:58PM CST
biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis or the "Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier ("BBB" , announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company's Transcend BBB delivery vector.
BTI.VN: 1.390 (unch)
biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies -- Inclusive of Trastuzumab -- to Treat Her2/neu Brain Metastases
Marketwire Canada - Tue Nov 10, 4:00PM CST
BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the full and final issuance of a US patent covering the delivery by Transcend of cancer therapeutics to the brain to treat an aggressive form of brain cancer -- Her2+/nue brain metastases.
BTI.VN: 1.390 (unch)
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review Report H2 2015
M2 - Mon Nov 09, 9:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/zxt8qr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2015" report to their offering. The report Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2015', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and special features on late-stage and discontinued projects. Companies Mentioned - Alexion Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Laboratorios Del Dr. Esteve S.A. - RegenxBio Inc. - Sangamo BioSciences, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/zx...saccharido
FATE: 1.98 (+0.11), SHPG: 191.43 (-3.01), SGMO: 6.16 (-0.18), ALXN: 130.40 (+0.62)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Review, H2 2015 - 10 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2932sl/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - ArmaGen Technologies, Inc. - Athersys, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - OPKO Health, Inc. - PTC Therapeutics, Inc. - RegenxBio Inc. - Sangamo BioSciences, Inc. Drug Profiles - AGT-181 - ataluren - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - FT-1050 - laronidase chaperone - MultiStem - Oligonucleotide for Mucopolysaccharidosis I - Recombinant Enzyme to Replace Alpha-L-Iduronidase for Hurler Syndrome - Recombinant Enzyme to Target LRP1 for Mucopolysaccharidosis I - RGX-111 - SB-318 - Stem Cell Therapy for Type1 Mucopolysaccharidosis For more information visit http://www.researchandmarkets.com/research/29...saccharido
FATE: 1.98 (+0.11), OPK: 9.89 (-0.06), SGMO: 6.16 (-0.18), PTCT: 5.77 (+0.06), ATHX: 2.20 (+0.02), FOLD: 6.80 (-0.33)
biOasis Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 28, 4:16PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company" wishes to announce, that as part of its going forward strategy, its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company's trading symbol will remain BIOAF.
BTI.VN: 1.390 (unch)
TSX Venture Exchange Daily Bulletins
CNW Group - Thu Aug 27, 3:31PM CDT
TSX VENTURE COMPANIES
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 289.03 (+0.68), ATNM: 1.75 (+0.05), AMGN: 171.28 (+0.60), CELGZ: 1.17 (-0.02)
biOasis to extend share purchase warrants exercise date
M2 - Mon Aug 17, 7:35AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE: BTI) said on Friday that it plans to extend the exercise date of its 1,599,477 warrants currently exercisable until 29 August 2015 to 31 December 2015.
BTI.VN: 1.390 (unch)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 1.75 (+0.05), ADRO: 14.92 (-0.01), AMBX: (), AZN: 34.29 (+2.75), AMGN: 171.28 (+0.60), AMPE: 0.99 (+0.03), ABBV: 64.72 (-0.18), BMY: 74.66 (-1.81), AAAP: 31.00 (+0.02)
biOasis Announces Extension of Share Purchase Warrants
Marketwired - Fri Aug 14, 12:00PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" wishes to announce that it will make an application to extend the exercise date of its 1,599,477 warrants currently exercisable until August 29, 2015 (the "Warrants" . The Warrants were issued with an original term of 12 months in connection with the closing of a private placement financing as announced by the Company on August 29, 2015. A total of 30,530 of the Warrants are held by an insider of the Company who participated in the private placement. The extension of the expiry of the Warrants is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 ("MI 61-101" by virtue of the exemptions contain in section 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company issued to an insider does not exceed 25% of its market capitalization.
BTI.VN: 1.390 (unch)
biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC
Marketwired - Thu Apr 21, 5:28PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company"
announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC ("Astellas" . The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the internalization and assessment of the biOasis Transcend technology. BTI.VN: 1.390 (unch)
biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain
Marketwired - Thu Mar 17, 10:37PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company"
on Saturday, March 19, 2016 at 11:45am, will present the data from the biOasis sponsored Brains for Brain ("B4B" lysosomal storage disease ("LSD" knockout mouse study performed by Dr. Maurizio Scarpa and Dr. Rosella Tomanin at Dr. Scarpa's laboratories in Padova, Italy. Dr. Scarpa is a world leading clinical expert in lysosomal storage diseases. BTI.VN: 1.390 (unch)
biOasis Technologies Inc. - Product Pipeline Review Market Size, Share & Forecast to 2015: Radiant Insights, Inc
M2 - Fri Jan 22, 3:06AM CST
Summary
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 36.67 (-0.18), SPPI: 6.82 (-0.02), BMY: 74.66 (-1.81), STML: 7.45 (-0.06), ONTY: 1.21 (+0.02), NKTR: 16.10 (+0.93), MEIP: 1.36 (-0.02), ATNM: 1.75 (+0.05), ABBV: 64.72 (-0.18), EXEL: 8.95 (+0.19), NVS: 82.08 (-0.81)
Kalytera Therapeutics elects Ronald P. Erickson to board
M2 - Fri Dec 04, 6:05AM CST
Pharmaceutical company Kalytera Therapeutics revealed on Thursday the addition of Ronald P. Erickson to its board of directors.
Kalytera Therapeutics Appoints Ronald P. Erickson to Board of Directors
Marketwired - Thu Dec 03, 6:08PM CST
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid ("CBD"
and synthetic CBD medicines intended to address the unmet needs of large patient populations, today announced it has appointed Ronald P. Erickson to its Board of Directors. biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
Marketwired - Sun Nov 29, 2:58PM CST
biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis or the "Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier ("BBB"
, announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company's Transcend BBB delivery vector. BTI.VN: 1.390 (unch)
biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies -- Inclusive of Trastuzumab -- to Treat Her2/neu Brain Metastases
Marketwire Canada - Tue Nov 10, 4:00PM CST
BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the full and final issuance of a US patent covering the delivery by Transcend of cancer therapeutics to the brain to treat an aggressive form of brain cancer -- Her2+/nue brain metastases.
BTI.VN: 1.390 (unch)
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review Report H2 2015
M2 - Mon Nov 09, 9:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/zxt8qr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2015" report to their offering. The report Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2015', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and special features on late-stage and discontinued projects. Companies Mentioned - Alexion Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Laboratorios Del Dr. Esteve S.A. - RegenxBio Inc. - Sangamo BioSciences, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/zx...saccharido
FATE: 1.98 (+0.11), SHPG: 191.43 (-3.01), SGMO: 6.16 (-0.18), ALXN: 130.40 (+0.62)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Review, H2 2015 - 10 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2932sl/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - ArmaGen Technologies, Inc. - Athersys, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - OPKO Health, Inc. - PTC Therapeutics, Inc. - RegenxBio Inc. - Sangamo BioSciences, Inc. Drug Profiles - AGT-181 - ataluren - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - FT-1050 - laronidase chaperone - MultiStem - Oligonucleotide for Mucopolysaccharidosis I - Recombinant Enzyme to Replace Alpha-L-Iduronidase for Hurler Syndrome - Recombinant Enzyme to Target LRP1 for Mucopolysaccharidosis I - RGX-111 - SB-318 - Stem Cell Therapy for Type1 Mucopolysaccharidosis For more information visit http://www.researchandmarkets.com/research/29...saccharido
FATE: 1.98 (+0.11), OPK: 9.89 (-0.06), SGMO: 6.16 (-0.18), PTCT: 5.77 (+0.06), ATHX: 2.20 (+0.02), FOLD: 6.80 (-0.33)
biOasis Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 28, 4:16PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company"
wishes to announce, that as part of its going forward strategy, its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company's trading symbol will remain BIOAF. BTI.VN: 1.390 (unch)
TSX Venture Exchange Daily Bulletins
CNW Group - Thu Aug 27, 3:31PM CDT
TSX VENTURE COMPANIES
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 289.03 (+0.68), ATNM: 1.75 (+0.05), AMGN: 171.28 (+0.60), CELGZ: 1.17 (-0.02)
biOasis to extend share purchase warrants exercise date
M2 - Mon Aug 17, 7:35AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE: BTI) said on Friday that it plans to extend the exercise date of its 1,599,477 warrants currently exercisable until 29 August 2015 to 31 December 2015.
BTI.VN: 1.390 (unch)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 1.75 (+0.05), ADRO: 14.92 (-0.01), AMBX: (), AZN: 34.29 (+2.75), AMGN: 171.28 (+0.60), AMPE: 0.99 (+0.03), ABBV: 64.72 (-0.18), BMY: 74.66 (-1.81), AAAP: 31.00 (+0.02)
biOasis Announces Extension of Share Purchase Warrants
Marketwired - Fri Aug 14, 12:00PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company"
wishes to announce that it will make an application to extend the exercise date of its 1,599,477 warrants currently exercisable until August 29, 2015 (the "Warrants" . The Warrants were issued with an original term of 12 months in connection with the closing of a private placement financing as announced by the Company on August 29, 2015. A total of 30,530 of the Warrants are held by an insider of the Company who participated in the private placement. The extension of the expiry of the Warrants is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 ("MI 61-101" by virtue of the exemptions contain in section 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company issued to an insider does not exceed 25% of its market capitalization. BTI.VN: 1.390 (unch)
